AU Patent

AU2020360413A1 — Methods of treating conditions related to the S1P1 receptor

Assigned to Arena Pharmaceuticals Inc · Expires 2022-04-14 · 4y expired

What this patent protects

Provided are methods of treatment of Crohn's Disease comprising prescribing and/or administering to an individual in need thereof a standard dose of (

USPTO Abstract

Provided are methods of treatment of Crohn's Disease comprising prescribing and/or administering to an individual in need thereof a standard dose of (

Drugs covered by this patent

Velsipity (Etrasimod Arginine) · Pfizer Inc.

Patent Metadata

Patent number: AU2020360413A1
Jurisdiction: AU
Classification: —
Expires: 2022-04-14
Drug substance claim: No
Drug product claim: No
Assignee: Arena Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.